ATE482272T1 - Zytokinproteinfamilie - Google Patents
ZytokinproteinfamilieInfo
- Publication number
- ATE482272T1 ATE482272T1 AT08153475T AT08153475T ATE482272T1 AT E482272 T1 ATE482272 T1 AT E482272T1 AT 08153475 T AT08153475 T AT 08153475T AT 08153475 T AT08153475 T AT 08153475T AT E482272 T1 ATE482272 T1 AT E482272T1
- Authority
- AT
- Austria
- Prior art keywords
- protein family
- cytokine protein
- amino acid
- seq
- acid residues
- Prior art date
Links
- 102000004127 Cytokines Human genes 0.000 title 1
- 108090000695 Cytokines Proteins 0.000 title 1
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28542401P | 2001-04-20 | 2001-04-20 | |
| US28540801P | 2001-04-20 | 2001-04-20 | |
| US28648201P | 2001-04-25 | 2001-04-25 | |
| US09/895,834 US6927040B2 (en) | 2000-06-30 | 2001-06-29 | Interferon-like protein Zcyto21 |
| US34110501P | 2001-10-22 | 2001-10-22 | |
| US34105001P | 2001-10-22 | 2001-10-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE482272T1 true ATE482272T1 (de) | 2010-10-15 |
Family
ID=27559579
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08153475T ATE482272T1 (de) | 2001-04-20 | 2002-04-19 | Zytokinproteinfamilie |
| AT02764322T ATE403726T1 (de) | 2001-04-20 | 2002-04-19 | Cytokin-proteinfamilie |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02764322T ATE403726T1 (de) | 2001-04-20 | 2002-04-19 | Cytokin-proteinfamilie |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP1501936B1 (de) |
| JP (1) | JP4350950B2 (de) |
| CN (2) | CN100482684C (de) |
| AT (2) | ATE482272T1 (de) |
| AU (1) | AU2002307510A1 (de) |
| BR (1) | BR0205083A (de) |
| CA (1) | CA2441958C (de) |
| DE (2) | DE60228136D1 (de) |
| DK (1) | DK1501936T3 (de) |
| ES (1) | ES2311622T3 (de) |
| RU (1) | RU2321594C2 (de) |
| WO (1) | WO2002086087A2 (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1356046T3 (da) | 2000-11-28 | 2010-03-01 | Zymogenetics L L C | Cytokinreceptor zcytoR19 |
| US7033787B2 (en) * | 2001-12-21 | 2006-04-25 | Ludwig Institute For Cancer Research | Isolated cytokine receptor LICR-2 |
| EP1497415B1 (de) * | 2002-04-19 | 2010-12-29 | ZymoGenetics, L.L.C. | Verfahren zum nachweis oder zur modulierung der wechselwirkung eines cytokinrezeptors mit seinem ligand |
| JP2006509041A (ja) | 2002-10-23 | 2006-03-16 | ザイモジェネティクス，インコーポレイティド | Ｉｌ−２８およびｉｌ−２９を用いるウイルス感染を治療するための方法 |
| PT2251353E (pt) | 2003-08-07 | 2013-05-07 | Zymogenetics Inc | Preparações homogéneas de il-28 e il-29 |
| JP4896005B2 (ja) * | 2004-04-02 | 2012-03-14 | ザイモジェネティクス リミテッド ライアビリティ カンパニー | Ｉｌ−２８およびｉｌ−２９システイン変異体を用いるウイルス感染を治療するための方法 |
| RU2389502C2 (ru) * | 2004-07-29 | 2010-05-20 | Займодженетикс, Инк. | Применение il-28 и il-29 для лечения карциномы и аутоиммунных нарушений |
| WO2006012644A2 (en) * | 2004-07-29 | 2006-02-02 | Zymogenetics, Inc. | Use of il-28 and il-29 to treat cancer |
| AU2006272937A1 (en) | 2005-07-20 | 2007-02-01 | Bristol-Myers Squibb Company | Use of truncated cysteine IL28 and IL29 mutants to treat cancers and autoimmune disorders |
| EP2201035B1 (de) * | 2007-09-20 | 2015-06-17 | Commonwealth Scientific and Industrial Research Organisation | Neue vogel-zytokine und für diese codierende genetische sequenzen |
| JP5821198B2 (ja) * | 2011-01-27 | 2015-11-24 | 富士レビオ株式会社 | 抗ｉｌ２８ｂ抗体及びこれを用いたｉｌ２８ｂの測定方法 |
| FR2975185A1 (fr) * | 2011-05-12 | 2012-11-16 | Univ Claude Bernard Lyon | Procede de determination in vitro de la presence d'une sclerose en plaques |
| WO2013024158A1 (en) | 2011-08-17 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection |
| WO2013024156A2 (en) | 2011-08-17 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection |
| WO2014033266A1 (en) | 2012-08-31 | 2014-03-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection |
| CN110894525A (zh) * | 2018-09-12 | 2020-03-20 | 贵州大学 | 从江香猪IFN-λ1基因的检测方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CY1346A (en) * | 1980-01-08 | 1987-01-16 | Biogen Nv | Dna sequences,recombinant dna molecules and processes for producing human interferon-like polypeptides |
| RU2143491C1 (ru) * | 1994-07-13 | 1999-12-27 | Санкио Компани Лимитед | Полинуклеотидная последовательность (варианты), полипептид (варианты), слитый белок, фармацевтическая композиция, моноклональное антитело, штамм гибридных культивируемых клеток |
| US5945511A (en) | 1997-02-20 | 1999-08-31 | Zymogenetics, Inc. | Class II cytokine receptor |
| ES2223127T3 (es) * | 1997-04-25 | 2005-02-16 | Zymogenetics, Inc. | Factor 7 mamario del tipo citoquina. |
| US5924404A (en) | 1997-10-24 | 1999-07-20 | Brunswick Corporation | Cylinder-specific spark ignition control system for direct fuel injected two-stroke engine |
| BR9914777A (pt) | 1998-10-26 | 2001-07-03 | Ludwig Inst Cancer Res | Moléculas isoladas de ácido nucléico que codificam os fatores induzìveis por células t (tifs), as proteìnas codificadas e os usos das mesmas |
| AR021876A1 (es) | 1998-12-18 | 2002-08-07 | Schering Corp | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado |
| AU3891600A (en) * | 1999-03-18 | 2000-10-04 | Zymogenetics Inc. | Murine interferon-alpha named also zcyto13 |
| US6391948B1 (en) | 1999-12-14 | 2002-05-21 | 3M Innovative Properties Company | Triazine compounds and use thereof |
| US20030104579A1 (en) * | 2001-05-10 | 2003-06-05 | Baum Peter R. | Cytokine polypeptides |
| WO2003066002A2 (en) * | 2002-02-08 | 2003-08-14 | University Of Medicine And Dentistry Of New Jersey | IFN-a/b-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION |
-
2002
- 2002-04-19 BR BR0205083-8A patent/BR0205083A/pt not_active IP Right Cessation
- 2002-04-19 DK DK02764322T patent/DK1501936T3/da active
- 2002-04-19 EP EP02764322A patent/EP1501936B1/de not_active Expired - Lifetime
- 2002-04-19 CA CA2441958A patent/CA2441958C/en not_active Expired - Fee Related
- 2002-04-19 DE DE60228136T patent/DE60228136D1/de not_active Expired - Lifetime
- 2002-04-19 CN CNB028019709A patent/CN100482684C/zh not_active Expired - Fee Related
- 2002-04-19 CN CNA2009101265085A patent/CN101531715A/zh active Pending
- 2002-04-19 AT AT08153475T patent/ATE482272T1/de not_active IP Right Cessation
- 2002-04-19 DE DE60237791T patent/DE60237791D1/de not_active Expired - Lifetime
- 2002-04-19 WO PCT/US2002/012887 patent/WO2002086087A2/en not_active Ceased
- 2002-04-19 ES ES02764322T patent/ES2311622T3/es not_active Expired - Lifetime
- 2002-04-19 EP EP08153475A patent/EP1942187B1/de not_active Expired - Lifetime
- 2002-04-19 JP JP2002583602A patent/JP4350950B2/ja not_active Expired - Fee Related
- 2002-04-19 RU RU2003133748/13A patent/RU2321594C2/ru not_active IP Right Cessation
- 2002-04-19 AU AU2002307510A patent/AU2002307510A1/en not_active Abandoned
- 2002-04-19 AT AT02764322T patent/ATE403726T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| CN100482684C (zh) | 2009-04-29 |
| EP1501936A4 (de) | 2005-07-20 |
| RU2003133748A (ru) | 2005-05-10 |
| DE60228136D1 (de) | 2008-09-18 |
| WO2002086087A3 (en) | 2004-11-18 |
| EP1942187B1 (de) | 2010-09-22 |
| CA2441958A1 (en) | 2002-10-31 |
| CN1620510A (zh) | 2005-05-25 |
| DK1501936T3 (da) | 2008-12-08 |
| JP4350950B2 (ja) | 2009-10-28 |
| BR0205083A (pt) | 2004-07-20 |
| ATE403726T1 (de) | 2008-08-15 |
| CN101531715A (zh) | 2009-09-16 |
| EP1942187A1 (de) | 2008-07-09 |
| AU2002307510A1 (en) | 2002-11-05 |
| DE60237791D1 (de) | 2010-11-04 |
| ES2311622T3 (es) | 2009-02-16 |
| RU2321594C2 (ru) | 2008-04-10 |
| EP1501936A2 (de) | 2005-02-02 |
| JP2005506052A (ja) | 2005-03-03 |
| WO2002086087A2 (en) | 2002-10-31 |
| CA2441958C (en) | 2012-01-17 |
| EP1501936B1 (de) | 2008-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE403726T1 (de) | Cytokin-proteinfamilie | |
| ATE536406T1 (de) | Neuartiger zytokin-zcytor17-ligand | |
| ATE295414T1 (de) | Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen | |
| DE60135393D1 (de) | Allelische Variante des Interferon-ähnlichen Proteins Zcyto21 | |
| ATE269902T1 (de) | Cytokinähnliches polypeptid-10 aus säugetieren | |
| ATE495247T1 (de) | Chromoprotein und fluoroproteine | |
| ATE441713T1 (de) | Tumorantigenprotein und dessen verwendung | |
| ATE432985T1 (de) | Polypeptide mit aktivität der stimulierung von neutrophilen | |
| EP1467207A4 (de) | Screening-verfahren | |
| ATE409747T1 (de) | Mit wt1 interagierendes protein, wtip |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |